ClinicalTrials.gg
Not yet recruitingNCT07905196Updated Oct 29, 2026

Anesthetic Effectiveness of Mental/Incisive Nerve Block Versus Inferior Nerve Block Using 4% Articaine and 2% Lidocaine in Mandibular First and Second Premolars With Symptomatic Irreversible Pulpitis.

An interventional study of Group A : MINB with 2% Lidocaine HCL+ 1:1000,000 Epinephrine - 1.8 ml and Group B : MINB with 4% Articaine HCL + 1:1000,000 Epinephrine - 1.8 ml in Pain, sponsored by Foundation University Islamabad. Not yet recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Foundation University Islamabad · Not applicable, Interventional, and Treatment

Updated Oct 29, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to check the anesthetic effectiveness of 4% Articaine and 2% Lidocaine in IANB Vs Mental nerve block in 1st and 2nd premolars with symptomatic Irreversible Pulpitis. This study aims to compare and find the best possible anesthetic solution amongst 2% Lidocaine and 4% Articaine and technique ie IANB Vs Mental Nerve block to make endodontic procedure pain free or comfortable for the patient

Read the detailed description

This study will be including four treatment groups. Conducted as a single blind Randomized control Trial i.e. 2x2 Factorial Design. Primary purpose will be to evaluate the main effect of injection technique , main effect of anesthetic solution and potential interaction between 2 solutions.

This study will be conducted in Department of Operative Dentistry and Endodontics, Foundation University College of dentistry and Hospital , following approval from Institutional Ethical Review committee A total of 108 participants will be recruited. The calculation was based on previously reported anesthetic success rates for MINB and IANB using 2% Lidocaine and 4% Articaine Participants reporting to operative Dentistry department with Symptomatic Irreversible pulpitis in mandibular first and second premolars. Participants meeting inclusion criteria will be invited.

PRE OPERATIVE CLINICAL ASSESMENT will be done i.e. Age , Gender , relevant medical history , Current medications , History of allergies to LA or related components, Any previous anesthesia related events , Intensity of pain before treatment , Presence duration and characteristics of pain. Any condition that may contraindicate the administration of anesthesia Diagnosis of Symptomatic Irreversible pulpitis will be done using a combination of patients history , clinical examination , cold testing and Radiographic evaluation , Pre operative pain assessment using NRS Numerical rating scale from O-10 ADMINSTRATION OF LOCAL ANESTHESIA For MINB groups, 1.8ml of the assigned anesthetic will be deposited in the region of mental foramen after negative aspiration For IANB groups, 1.8ml of the assigned anesthetic will be administered using conventional inferior alveolar nerve block technique after negative aspiration A standardized 15 mins waiting period will be observed after injection. Soft tissue assessment will be done by subjective numbness/probing of buccal gingiva.

PAIN ASSESMENT pain will be recorded using NRS during

  1. Access cavity preparation
  2. Pulp extirpation The outcome accessor will remain blinded DEFINITION OF ANESTHETIC SUCCESS Success : NRS 0-3 During treatment without the need for supplemental anesthesia Failure : NRS >3 requiring supplemental anesthesia DATA COLLECTION Following will be recorded Age and gender , tooth type , Pre operative and cold test pain scores , Injection technique , Anesthetic Solution, Soft tissue numbness , intraoperative pain , Any need for supplemental anesthesia , Injection related complications.

PRIMARY OUTCOME

The analysis will evaluate:

  1. Main effect of injection technique
  2. Main effect of anesthetic solution
  3. Interaction between injection technique and anesthetic solution SAFETY any complications including injection site discomfort , hematoma , persistent numbness or other adverse events will be documented and managed according to standard protocols
02

Conditions studied

  • Pain

Browse trials for

Keywords

  • Pain
03

In context

Pain

10,054 studies on the registry are indexed under Pain; 1,649 are open to participants now.

This study's planned enrollment of 108 is above the median of 66 across 8,493 interventional studies indexed under Pain.

Browse Pain studies →

Lead sponsor

Foundation University Islamabad is the lead sponsor of 255 studies on the registry; 142 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 55 years.
  • Mandibular first and second premolars presenting with symptomatic irreversible pulpitis.
  • Positive cold test.

Exclusion criteria

Exclusion Criteria:

  • Allergy or to any component of local anesthesia.
  • History of confirmed or suspected substance abuse.
  • Radiographic evidence of periapical pathology.
  • Advanced periodontal disease.
  • Lack of soft tissue numbness 15 mins after assigned anesthetic technique.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Outcomes assessor)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Group A: MINB + 2% Lidocaine

    Group A will be administered 2% Lidocaine (1: 100,000 epi) using Mental nerve block technique

    Procedure: Group A : MINB with 2% Lidocaine HCL+ 1:1000,000 Epinephrine - 1.8 ml

  • Experimental
    Group A: MINB + 4% Articaine

    Group B will be administered 4% Articaine (1: 100,000 epi) using Mental nerve block technique

    Procedure: Group B : MINB with 4% Articaine HCL + 1:1000,000 Epinephrine - 1.8 ml

  • Experimental
    Group C : IANB + 2% Lidocaine

    Group C will be administered 2% lidocaine (1: 100,000 epi) using Inferior Alveolar nerve block technique

    Procedure: Group C : IANB with 2% Lidocaine HCL + 1:1000,000 Epinephrine - 1.8 ml

  • Experimental
    Group D : IANB + 4% Articaine

    Group D will be administered 4% Articaine (1: 100,000 epi) using Inferior Alveolar nerve block technique

    Procedure: Group D : IANB with 4% Articaine HCL + 1:1000,000 Epinephrine - 1.8 ml

Interventions

  • ProcedureGroup A : MINB with 2% Lidocaine HCL+ 1:1000,000 Epinephrine - 1.8 ml

    Group A will be administered with 2% Lidocaine HCL + 1:1000,000 Epinephrine - 1.8 ml through Mental/Incisive nerve block technique

  • ProcedureGroup B : MINB with 4% Articaine HCL + 1:1000,000 Epinephrine - 1.8 ml

    Group B will be administered with 4% Articaine HCL + 1:1000,000 Epinephrine - 1.8 ml through Mental/Incisive nerve block technique

  • ProcedureGroup C : IANB with 2% Lidocaine HCL + 1:1000,000 Epinephrine - 1.8 ml

    Group C will be administered with 2% Lidocaine HCL + 1:1000,000 Epinephrine - 1.8 ml through Inferior Alveolar nerve block technique

  • ProcedureGroup D : IANB with 4% Articaine HCL + 1:1000,000 Epinephrine - 1.8 ml

    Group D will be administered with 4% Articaine HCL + 1:1000,000 Epinephrine - 1.8 ml through inferior alveolar nerve block

06

What researchers measure

Primary outcomes

  1. Anesthetic Success Rate

    Anesthetic success rate defined as completing access cavity preparation + pulp extirpation with 1. Success : NRS 0-3 ( No pain/ Mild pain) WITHOUT need for supplemental anesthesia 2. Failure : NRS\>3 ( Moderate/Severe pain) requiring supplemental anesthesia

    Time frame: Periprocedural and Intraprocedural 1) Preprocedural Assessment of pain on NRS scale (0-10) 2)Intra- Procedural Outcome is Assessed at 15 minutes after giving anesthesia. If no numbness after 15 minutes the patient is excluded from the study.

Secondary outcomes

  1. Pain scores (NRS 0-10) at 4 time points

    Pain scores recorded at 4 time points 1. Preoperative pain 2. Pain response to Cold test 3. Pain during access cavity preparation 4. Pain during pulp extirpation

    Time frame: Intraoperative

  2. Soft tissue anesthesia success

    Presence of soft tissue numbness at 15 mins post-injection assessed by tactile sensation + gentle probing of buccal gingiva

    Time frame: Intraoperative

  3. Need for Supplemental Anesthesia

    Yes/No and Type : Intra ligamental/Additional block/Buccal Infiltration /Intra pulpal

    Time frame: Intraoperative

  4. Complications

    Complications after anesthesia can occur like Persistent numbness/Hematoma /Discomfort at injection site /

    Time frame: Intraoperative/ Postoperative

07

Study locations

1 site
08

References and documents

Publications

  • Ghabraei S, Shubbar A, Nekoofar MH, Nosrat A. Anesthetic efficacy of mental/incisive nerve block compared to inferior alveolar nerve block using 4% articaine in mandibular premolars with symptomatic irreversible pulpitis: a randomized clinical trial. Clin Oral Investig. 2019 Feb;23(2):839-845. doi: 10.1007/s00784-018-2500-4. Epub 2018 Jun 7. PubMed 29882110 ↗
  • Aggarwal V, Singla M, Miglani S, Kohli S. Comparative Evaluation of Mental Incisal Nerve Block, Inferior Alveolar Nerve Block, and Their Combination on the Anesthetic Success Rate in Symptomatic Mandibular Premolars: A Randomized Double-blind Clinical Trial. J Endod. 2016 Jun;42(6):843-5. doi: 10.1016/j.joen.2016.02.015. Epub 2016 Apr 14. PubMed 27086046 ↗
  • Lozano Gonzalez O, Salas Orozco MF, Trigueros Mancera J, Martinez Cuellar NG, Luna Dominguez C, Rosales Garcia P. Anesthetic Efficacy of Mental/Incisive Nerve Block Versus Inferior Alveolar Nerve Block in Mandibular Premolars With Symptomatic Irreversible Pulpitis: A Systematic Review and Meta-Analysis. Cureus. 2025 Nov 10;17(11):e96492. doi: 10.7759/cureus.96492. eCollection 2025 Nov. PubMed 41384210 ↗
  • Saha SG, Jain S, Dubey S, Kala S, Misuriya A, Kataria D. Effect of Oral Premedication on the Efficacy of Inferior Alveolar Nerve Block in Patients with Symptomatic Irreversible Pulpitis: A Prospective, Double-Blind, Randomized Controlled Clinical Trial. J Clin Diagn Res. 2016 Feb;10(2):ZC25-9. doi: 10.7860/JCDR/2016/16873.7195. Epub 2016 Feb 1. PubMed 27042580 ↗
  • Sulek T, Dumani A, Kuden C, Kussever H, Yoldas O. Anesthetic Effectiveness of Mental/Incisive Nerve Block versus Inferior Alveolar Nerve Block in Mandibular First and Second Premolars with Symptomatic Irreversible Pulpitis: A Randomized Clinical Trial. J Endod. 2025 Apr;51(4):473-480. doi: 10.1016/j.joen.2025.01.016. Epub 2025 Jan 27. PubMed 39880189 ↗
  • Karapinar-Kazandag M, Tanalp J, Ersev H. Effect of Premedication on the Success of Inferior Alveolar Nerve Block in Patients with Irreversible Pulpitis: A Systematic Review of the Literature. Biomed Res Int. 2019 Feb 10;2019:6587429. doi: 10.1155/2019/6587429. eCollection 2019. PubMed 30881994 ↗

Related links

Individual participant data

Plan to share: Undecided

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07905196
Responsible party
Shoaib Rahim (Associate Professor, Foundation University Islamabad) — Principal investigator
First posted
Oct 29, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Gul Andama Ihsan, FCPS Resident
Contact
gulihsan949@gmail.com
03331629743
Dr Nadia Aman, FCPS
Contact
clinicaltrials.fucd@fui.edu.pk
03022526440
Clinical T FUCD
principal investigator · Foundation University Islamabad

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion